Fonte: Cell Death & Disease. Unidade: FMRP
Assuntos: ANTINEOPLÁSICOS, DOENÇAS DO SISTEMA NERVOSO PERIFÉRICO, FARMACOTERAPIA, DOR CRÔNICA
ABNT
BRANDOLINI, Laura et al. Paclitaxel binds and activates C5aR1: a new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions. Cell Death & Disease, v. 13, n. 5, p. 1-15, 2022Tradução . . Disponível em: https://doi.org/10.1038/s41419-022-04964-w. Acesso em: 12 jul. 2024.APA
Brandolini, L., d’Angelo, M., Novelli, R., Castelli, V., Giorgio, C., Sirico, A., et al. (2022). Paclitaxel binds and activates C5aR1: a new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions. Cell Death & Disease, 13( 5), 1-15. doi:10.1038/s41419-022-04964-wNLM
Brandolini L, d’Angelo M, Novelli R, Castelli V, Giorgio C, Sirico A, Cocchiaro P, D’Egidio F, Benedetti E, Cristiano C, Bugatti A, Quadros AU de, Cunha TM. Paclitaxel binds and activates C5aR1: a new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions [Internet]. Cell Death & Disease. 2022 ; 13( 5): 1-15.[citado 2024 jul. 12 ] Available from: https://doi.org/10.1038/s41419-022-04964-wVancouver
Brandolini L, d’Angelo M, Novelli R, Castelli V, Giorgio C, Sirico A, Cocchiaro P, D’Egidio F, Benedetti E, Cristiano C, Bugatti A, Quadros AU de, Cunha TM. Paclitaxel binds and activates C5aR1: a new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions [Internet]. Cell Death & Disease. 2022 ; 13( 5): 1-15.[citado 2024 jul. 12 ] Available from: https://doi.org/10.1038/s41419-022-04964-w